Catalysing partnerships - Personalised Medicine Consortium / Health Sciences and Technologies in Luxembourg / Portrait / Luxembourg BioHealth Cluster

Luxembourg Cluster Portal

Luxembourg – an attractive location for research, development and innovation

Luxembourg BioHealth Cluster

The Luxembourg Government has identified the fast-growing Healthcare Biotech sector as a key innovation driver to foster economic diversification ...

Luxembourg EcoInnovation Cluster

Luxembourg hosts a thriving eco-innovation sector. There are numerous eco-companies in the country...

Luxembourg ICT Cluster

The Luxembourg ICT Cluster is a network that supports the various actors in the field of ICT in Luxembourg with the goal of creating and developing new sustainable business opportunities.

Luxembourg Materials Cluster

Luxembourg’s strong track record in the manufacture and processing of many types of innovative materials is well proven with internationally renowned companies...

Luxembourg Space Cluster

The Luxembourg Space Cluster brings together renowned and highly specialised companies and public research organisations in order to develop specific technology topics...

Luxembourg Cluster Portal Luxembourg BioHealth Cluster Luxembourg EcoInnovation Cluster Luxembourg ICT Cluster Luxembourg Materials Cluster Luxembourg Space Cluster

Catalysing partnerships - Personalised Medicine Consortium

The IBBL, the LCSB and the lung cancer demonstration project already act as three strong complementary pillars to catalyse collaborations within the Luxembourg research community, which is composed of more than 300 researchers divided into 6 public entities that include the IBBL, the LCSB and the CRP-Santé as well as the Life Sciences Research Unit of the University of Luxembourg, the “ Santec” Department of CRP-Tudor, dealing with health informatics and biomedical engineering, the Nutrition and Toxicology Research Unit of the CRP-Gabriel Lippman, and one private entity , namely the Laboratoire de Biologie Moléculaire et Cellulaire du Cancer. This portfolio of expertise and capabilities has been reinforced by the creation of the Luxembourg Clinical Proteomics Centre (LCP, CRP-Santé).

Public stakeholders involved in the Strategic Partnership Initiative are now formally associated within a Personalised Medicine Consortium (PMC) that focuses on four main priorities: cancer (lung, breast and colon), Parkinson’s disease, type II diabetes as well as a normal population cohort. This Consortium is open to any actor of the research and medical community that intends to contribute to these common projects.